The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular diseases that has no established therapy. The attribute of Lp(a) that affects cardiovascular risk is not established. Low levels of Lp(a) have been associated with type 2 diabetes (T2D). OBJECTIVES: This study investigated whether cardiovascular risk is conferred by Lp(a) molar concentration or apolipoprotein(a) [apo(a)] size, and whether the relationship between Lp(a) and T2D risk is causal. METHODS: This was a case-control study of 143,087 Icelanders with genetic information, including 17,715 with coronary artery disease (CAD) and 8,734 with T2D. This study used measured and genetically imputed Lp(a) molar concentration, kringle IV type 2 (KIV-2) repeats (which determine apo(a) size), and a splice variant in LPA associated with small apo(a) but low Lp(a) molar concentration to disentangle the relationship between Lp(a) and cardiovascular risk. Loss-of-function homozygotes and other subjects genetically predicted to have low Lp(a) levels were evaluated to assess the relationship between Lp(a) and T2D. RESULTS: Lp(a) molar concentration was associated dose-dependently with CAD risk, peripheral artery disease, aortic valve stenosis, heart failure, and lifespan. Lp(a) molar concentration fully explained the Lp(a) association with CAD, and there was no residual association with apo(a) size. Homozygous carriers of loss-of-function mutations had little or no Lp(a) and increased the risk of T2D. CONCLUSIONS: Molar concentration is the attribute of Lp(a) that affects risk of cardiovascular diseases. Low Lp(a) concentration (bottom 10%) increases T2D risk. Pharmacologic reduction of Lp(a) concentration in the 20% of individuals with the greatest concentration down to the population median is predicted to decrease CAD risk without increasing T2D risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Kettunen, J., Demirkan, A., Würtz, P., Draisma, H. H. M., Haller, T., Rawal, R., Vaarhorst, A., Kangas, A. J., Lyytikäinen, L.-P., Pirinen, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11122 · Cited by 738
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
Detection of sharing by descent, long-range phasing and haplotype imputation
Kong, A., Masson, G., Frigge, M. L., Gylfason, A., Zusmanovich, P., Thorleifsson, G., Olason, P. I., Ingason, A., Steinberg, S., Rafnar, T., et al. (2008) · Nature Genetics · doi:10.1038/ng.216 · Cited by 447 · cited 3×
“The sequence variants identified in subjects who underwent whole-genome sequencing were imputed into 151,677 Icelanders who had been genotyped with various Illumina (San Diego, California) SNP chips and their genotypes phased using long-range phasing (25,28) (Online Appendix).”
MethodSelf-citationLipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
Willeit, P., Kiechl, S., Kronenberg, F., Witztum, J. L., Santer, P., Mayr, M., Xu, Q., Mayr, A., Willeit, J., & Tsimikas, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.061 · Cited by 286
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels
Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Won, H.-H., Peloso, G. M., Stitziel, N. O., Nomura, A., Zekavat, S. M., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.033 · Cited by 244 · cited 1×
“We also replicated previous reports of association of Lp(a) with aortic valve stenosis (8), heart failure (34), ischemic stroke (driven by large-vessel disease) (3,35), and peripheral vascular disease (36), but not venous thromboembolism (37) or chronic kidney disease (38).”
ResultKamstrup, P. R., & Nordestgaard, B. G. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.08.006 · Cited by 206 · cited 1×
“We also replicated previous reports of association of Lp(a) with aortic valve stenosis (8), heart failure (34), ischemic stroke (driven by large-vessel disease) (3,35), and peripheral vascular disease (36), but not venous thromboembolism (37) or chronic kidney disease (38).”
ResultCoassin, S., Erhart, G., Weissensteiner, H., Eca Guimarães de Araújo, M., Lamina, C., Schönherr, S., Forer, L., Haun, M., Losso, J. L., Köttgen, A., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx174 · Cited by 93
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Mendelian randomization for cardiovascular diseases: Principles and applications
Larsson, S. C., Butterworth, A. S., & Burgess, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad736 · Cited by 735
Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review
Duarte Lau, F., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 363
Metadata
- Authors
- Gudbjartsson, D. F., Thorgeirsson, G., Sulem, P., Helgadottir, A., Gylfason, A., Saemundsdottir, J., Bjornsson, E., Norddahl, G. L., Jonasdottir, A., Jonasdottir, A., Eggertsson, H. P., Gretarsdottir, S., Thorleifsson, G., Indridason, O. S., Palsson, R., Jonasson, F., Jonsdottir, I., Eyjolfsson, G. I., Sigurdardottir, O., Olafsson, I., Danielsen, R., Matthiasson, S. E., Kristmundsdottir, S., Halldorsson, B. V., Hreidarsson, A. B., Valdimarsson, E. M., Gudnason, T., Benediktsson, R., Steinthorsdottir, V., Thorsteinsdottir, U., Holm, H., & Stefansson, K.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 74
- Issue
- 24
- Pages
- 2982-2994
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2992833268
- Cited by
- 226
- References
- 11
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.